MARKET

ENTA

ENTA

Enanta Pharmaceuticals Inc
NASDAQ
13.07
-0.16
-1.21%
Opening 12:20 07/16 EDT
OPEN
13.23
PREV CLOSE
13.23
HIGH
13.24
LOW
12.96
VOLUME
36.63K
TURNOVER
--
52 WEEK HIGH
17.15
52 WEEK LOW
6.44
MARKET CAP
380.05M
P/E (TTM)
-5.0370
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ENTA last week (0706-0710)?
Weekly Report · 3d ago
Weekly Report: what happened at ENTA last week (0629-0703)?
Weekly Report · 07/06 09:42
Enanta Pharmaceuticals Establishes Flexible At-The-Market Offering
TipRanks · 07/02 21:18
Enanta Pharmaceuticals Enters Open Market Sale Agreement With Jefferies; May Offer And Sell Up To $75M Of Common Stock Through Jefferies
Benzinga · 07/02 20:58
Enanta plans up to $75 million at-the-market stock offering via Jefferies
PUBT · 07/02 20:58
ENANTA PHARMACEUTICALS - MAY OFFER AND SELL UP TO $75 MLN OF COMMON STOCK THROUGH JEFFERIES - SEC FILING
Reuters · 07/02 20:56
Weekly Report: what happened at ENTA last week (0622-0626)?
Weekly Report · 06/29 09:39
Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last?
NASDAQ · 06/24 13:13
More
About ENTA
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The Company has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The Company also has development programs in virology for SARS-CoV-2 and Hepatitis B virus.

Webull offers Enanta Pharmaceuticals Inc stock information, including NASDAQ: ENTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENTA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ENTA stock methods without spending real money on the virtual paper trading platform.